Αρχική World News FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative... World News FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer Από Ogkologos - 20 Νοεμβρίου, 2024 829 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Spotlight On: Exercise Physiologists in Cancer Care 16 Νοεμβρίου, 2023 New Study Shows Intermittent Fasting May Reduce Breast Cancer Risk and... 26 Ιανουαρίου, 2021 Moving Beyond BMI: Low Muscle Mass May Affect Cancer Survival 30 Απριλίου, 2018 Medicare Open Enrollment is Here! 17 Οκτωβρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Extension of Indications for Dabrafenib and Trametinib Giving Myself the Most Time and Best Chance at Beating Cancer:... Olaparib after Initial Treatment Delays Ovarian Cancer Progression Breast Cancer Survivor Opens Her Own Business 17 Years After Beating...